Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and tolerability of rizatriptan in pediatric migraine (open-label)
2009-016375-30Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rizatriptan in migraine, migraine with aura and migraine without aura, sponsored by Merck & Co. Primary endpoint: Pain freedom at 2 hours postdose. Started Nov 2009; status: completed.
02
Drugs
rizatriptan
03
Conditions
migrainemigraine with auramigraine without aura
Beyond the preview
Go deeper on 2009-016375-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016375-30.